

15 April 2020

ASX ANNOUNCEMENT

ImpediMed Releases Heart Failure and Renal Disease Software

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), reported today a new software release that includes the HF-Dex™ heart failure assessment for the SOZO® Digital Health Platform. The new software also includes an assessment for patients with end stage renal disease (ESRD) as well as usability and data management improvements.

HF-Dex is a novel tool for the assessment of fluid overload in heart failure patients. Defined as extracellular fluid as a percent of total body water, HF-Dex is plotted against population-derived reference ranges and presented alongside extracellular fluid volume (ECF). Together these metrics provide physicians valuable information to risk-stratify patients as well as to monitor patient condition and response to therapy.

“Despite recent advances in treatment and management, heart failure continues to result in a high level of hospital readmissions and patient mortality,” said Dr. Andrew Accardi, Emergency Medicine Physician, Scripps Memorial Hospital. “We need better tools to easily and accurately assess changes in a patient’s condition. The data we are generating with SOZO are so promising, I expect it will have a very positive impact on patient care.”

Approximately 26 million people are living with heart failure, costing the global healthcare system about \$31 billion every year. After a single heart failure hospitalisation, nearly 25% of patients are readmitted within 30 days, and nearly 50% are readmitted in six months. The early detection of fluid build-up is critical to reducing hospital readmissions.

In addition to HF-Dex, the new software contains an assessment for patients with ESRD who are undergoing dialysis. Nearly 750,000 patients per year in the U.S. and an estimated 2 million patients worldwide are affected by ESRD. Those who live with ESRD are 1% of the U.S. Medicare population but account for 7% of the Medicare budget, or approximately US\$35 billion.

While it is widely accepted that better fluid management could reduce mortality and morbidity in dialysis patients, current devices and techniques, including monitoring and tracking tools, for improving fluid management are either inadequate or unproven, leaving no practical way to consistently maintain optimal volume status. SOZO provides an accurate, noninvasive, objective way to determine and monitor fluid levels in these patients.

“With this new software, we are bringing the benefits of SOZO to thousands of patients living with heart failure and renal disease,” said Richard Carreon, Managing Director and CEO of ImpediMed. “This is the power of our SaaS model. We can iterate quickly, respond to customer feedback, and deliver new features and tools that help healthcare providers care for their patients.”

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.